🎯 Drug Targets

Browse 3 drug targets with druggability analysis, composite scores, and clinical context

Targets

High Druggability

0.58

Avg Score

Target Classes

Druggability Distribution

High: 0Medium: 3Low: 0Unknown: 0

Avg druggability score: 0.527

Clinical Pipeline

Approved: 2Phase III: 0Phase II: 0Phase I: 1Preclinical: 0

Total compounds: 20 · Approved: 14

Filtered by: class=transcription_factor, druggability=Medium — 3 results

NR3C1 Glucocorticoid receptor Approved

Transcription Factor Medium Druggability

Selective glucocorticoid receptor modulators (SRMs) or antagonists

FOXO1 Forkhead box protein O1 Phase I

Transcription Factor Medium Druggability

Small molecule modulation of protein-DNA interactions or cofactor binding

TFAM Transcription factor A, mitochondrial Approved

Transcription Factor Medium Druggability

Drugs targeting TFAM would enhance or modulate its transcriptional activity to increase mitochondrial DNA replication and gene expression, thereby boosting mitochondrial biogenesis and ATP production. Alternatively, indirect approaches activate upstream regulators like PGC-1α and SIRT1 to increase TFAM expression and activity.